Filing Details

Accession Number:
0001415889-24-027239
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-11-19 16:36:19
Reporting Period:
2024-11-15
Accepted Time:
2024-11-19 16:36:19
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1845337 Day One Biopharmaceuticals Inc. DAWN Pharmaceutical Preparations (2834) 832415215
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1863107 Jeremy Bender 2000 Sierra Point Parkway, Suite 501
Brisbane CA 94005
Chief Executive Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-11-15 3,562 $0.00 102,494 No 4 M Direct
Common Stock Acquisiton 2024-11-15 4,750 $0.00 107,244 No 4 M Direct
Common Stock Acquisiton 2024-11-15 11,687 $0.00 118,931 No 4 M Direct
Common Stock Disposition 2024-11-18 10,554 $13.21 108,377 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Unit (RSU) Disposition 2024-11-15 3,562 $0.00 3,562 $0.00
Common Stock Restricted Stock Unit (RSU) Disposition 2024-11-15 4,750 $0.00 4,750 $0.00
Common Stock Restricted Stock Unit (RSU) Disposition 2024-11-15 11,687 $0.00 11,687 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
14,256 No 4 M Direct
38,000 No 4 M Direct
140,252 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 162,762 Indirect See footnote
Common Stock 219,406 Indirect See footnote
Common Stock 222,030 Indirect See footnote
Common Stock 197,614 Indirect See footnote
Common Stock 807,026 Indirect See footnote
Footnotes
  1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
  2. The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs.
  3. The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $13.02 to $13.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade.
  4. Represents shares held by The Jeremy Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 of which the Reporting Person is trustee.
  5. Represents shares held by The Jeremy Bender 2023 Grantor Retained Annuity Trust dated June 27, 2023.
  6. Represents shares held by The Melissa Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022of which the Reporting Person's spouse is trustee.
  7. Represents shares held by The Melissa Bender 2023 Grantor Retained Annuity Trust, dated June 27, 2023.
  8. Represents shares held by the Bender Revocable Trust dated January 18, 2017, as amended, Jeremy Bender and Melissa C. Bender, Trustees.
  9. The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
  10. RSUs do not expire; they either vest or are canceled prior to the vesting date.